Noigel is a research company focused on developing novel approaches to addressing a multitude of diseases
Based on scientific research spanning 4 decades our team of scientists are constantly applying and adapting scientific principles to repurpose existing drugs and to create novel therapeutics.
Pipeline
| Product | Category | Description | Preclinical | IND Filed | Phase 1 | Phase 2 | Phase 3 | NDA Filed | Market | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dipasol |
Wound Care |
None invasive composition stimulating the division, migration, and differentiation of autologous stem cells. |
|
||||||||||
| Product | Category | Description | Preclinical | IND Filed | Phase 1 | Phase 2 | Phase 3 | NDA Filed | Market | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Gemma |
Hemostatic Device |
In studies, Gemma has shown to stop bleeding 15 times faster than other commercially available hemostats. Gemma is a unique biodegradable composition that has minimal local and no systemic side effects. |
|
||||||||||
| Product | Category | Description | Preclinical | IND Filed | Phase 1 | Phase 2 | Phase 3 | NDA Filed | Market | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
F-RNA |
Antisense oligonucleotides |
Fragmentation of tRNA (fRNA) further modifying the structure of oligomeric fragments so that the fragments acquire not only the classical properties of antisense oligonucleotides, but also acquire opposite charges. |
|
||||||||||
| Product | Category | Description | Preclinical | IND Filed | Phase 1 | Phase 2 | Phase 3 | NDA Filed | Market | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NGL-025 |
MDR bacteria potentiator |
Novel composition to restore MDR bacterial sensitivity to old & new generation antibiotics. |
|
||||||||||
|
NGL-022 |
Nephroprotector (Polymyxin nephrotoxicity) |
Novel composition protecting kidneys Polymyxin nephrotoxicity. |
|
||||||||||
|
NGL-028 |
Novel antimicrobial |
The self-organizing superstructure of modified polyphenols, decreases the chance for (preventing) bacterial resistance. |
|
||||||||||
|
NGL-050 |
Suppression TB reactivation |
Composition stimulating completion of macrophage phagocytosis in granulomas and prevent TB reactivation. |
|
||||||||||
| Product | Category | Description | Preclinical | IND Filed | Phase 1 | Phase 2 | Phase 3 | NDA Filed | Market | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NGL-030 |
Modified Probiotics |
The novel approach to shorten the time of probiotics onset (bacillus coagulans) from 3-4 days to 2-3 hours. Thereby exponentially improving probiotic efficacy. |
|
||||||||||
| Product | Category | Description | Preclinical | IND Filed | Phase 1 | Phase 2 | Phase 3 | NDA Filed | Market | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NGL-040 |
Chronic Fatigue Syndrome |
The composition based on the activation of telomerase somatic cells, improving their viability leading to increased energy levels. |
|
||||||||||
| Product | Category | Description | Preclinical | IND Filed | Phase 1 | Phase 2 | Phase 3 | NDA Filed | Market | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NGL-070 |
Oral insulin |
The novel composition of modified Insulin for oral use. |
|
||||||||||
Publications
Influence of non-metabolic microbial growth promotors on the sensitivity to antimicrobials
The control over multi-resistant nosocomial strains of microorganisms has been becoming increasingly urgent in recent years.
Creation of new medical drugs based on Triz and computer mathematical modeling
The article provides an overview of the current state of the use of TRIZ in the pharmaceutical industry and our R&D efforts in that area
Accumulation activators and their influence on multi-drug resistance microorganisms
Pharmacological efficacy of a synergistic composition based on activators of cAMP accumulation as a wound healing agent
Wound-healing dipyridamole- and papaverine-based aerosols (D1/D2) are promising drugs that can accelerate wound healing in wound processes of various origins.
Noigel Pharma
Noigel is a research and development company focused on developing novel approaches to addressing unmet needs in a multitude of diseases. Based on scientific research spanning 4 decades our team of scientists is constantly applying and adapting scientific principles to repurpose existing drugs and to create novel therapeutics.
Management
Dr. Boris Farber
Chief Executive Officer
Dr. Boris Farber was named a Professional of the Year this year by Worldwide Branding for his impact and contributions to the field of Education, and R&D in Applied Mathematics, Bioengineering, Bio and Nanotechnologies.
Artur Martynov, Ph.D
Chief Science Officer
Head of laboratory and clinical department of molecular
immunopharmacology, Mechnicov institute of microbiology and immunology
Dr. Ilya Kleyn
Chief Medical Officer
With over 25 years of medical professional experience, Dr. Kleyn has certainly proven himself as an accomplished physician and talented medical researcher.
Avi Kamelhar
VP Business Development
Mr Kamelhar has over 20 years of experience in the healthcare management field, with a demonstrated track record in business development, contract negotiation, financial analysis and forecasting
Advisory Team
Daniel L. Beckles
M.D., Ph.D., FACS, FACC, FCCP
Dr. Beckles is double boarded by the American Board of Surgery and the American Board of Thoracic Surgery. He is a fellow of the American College of Surgeons, the American College of Cardiology and the American College of Chest Physicians.
Edwardo Mascareno
Ph.D
1996-1998 Post-Doctoral Fellow, Center for Cardiovascular and
Muscle Research, SUNY Downstate Medical Center,
1988-1990 Research Instructor, SUNY Downstate Medical Center,
1986-1988 Research Assistant, Avian Pathology, University Austral of Chile.
Noigel Journal
Marquis Who’s Who
Dr. Boris Farber Recognized for Excellence in his Career
Dr. Boris Farber, CEO of Noigel LLC; has been recognized as a VIP Member by Marquis Who’s Who for showing dedication, achievements, leadership abilities, excellence, and credentials in his career.
IAOTP
Dr. Ilya Kleyn selected as Top CMO & Physician Researcher of the Year by IAOTP
Dr. Ilya Kleyn was recently selected as Top CMO & Physician Researcher of the Year for 2022 by the International Association of Top Professionals (IAOTP) for his outstanding leadership, dedication and commitment to the Medical field and Pharmaceutical Research industry.
Superbugs & Superdrugs
An Interview with Boris Farber, CEO, Noigel LLC
Noigel LLC was established in 2010 by a group of scientists to study and develop drugs in areas such as: anticancer, antiviral and antimicrobial drugs with new properties.